This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the Phase III resuts for AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Ticker(s): AZNWho's the expert?
Institution: Midlantic Urology
- Manages 60 patients with urothelial cancer
- treats 40 patients with non-muscle-invasive bladder cancer
Interview GoalThis conversation will focus on the current treatment landscape and potential use of Truqap for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
